Search

Displaying results 6001 - 6010 of 10000 in total
  1. Drug

    Alnus incana subsp. rugosa pollen

    go.drugbank.com/drugs/DB10453
    Approved

    Alnus incana subsp. rugosa pollen is the pollen of the Alnus incana subsp. rugosa plant. Alnus incana subsp. rugosa pollen is mainly used in allergenic testing.

  2. Drug

    Xanthium strumarium var. canadense pollen

    go.drugbank.com/drugs/DB10462
    Approved

    Xanthium strumarium var. canadense pollen is the pollen of the Xanthium strumarium var. canadense plant. Xanthium strumarium var. canadense pollen is mainly used in allergenic testing.

  3. Drug

    Populus deltoides subsp. monilifera pollen

    go.drugbank.com/drugs/DB10465
    Approved

    Populus deltoides subsp. monilifera pollen is the pollen of the Populus deltoides subsp. monilifera plant. Populus deltoides subsp. monilifera pollen is mainly used in allergenic testing.

  4. Drug

    Populus balsamifera subsp. trichocarpa pollen

    go.drugbank.com/drugs/DB10754
    Approved

    Populus balsamifera subsp. trichocarpa pollen is the pollen of the Populus balsamifera subsp. trichocarpa plant. Populus balsamifera subsp. trichocarpa pollen is mainly used in allergenic testing.

  5. Drug

    Lolium perenne subsp. multiflorum pollen

    go.drugbank.com/drugs/DB10964
    Approved

    Lolium perenne subsp. multiflorum pollen is the pollen of the Lolium perenne subsp. multiflorum plant. Lolium perenne subsp. multiflorum pollen is mainly used in allergenic testing.

  6. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  7. Drug

    INCB3284

    go.drugbank.com/drugs/DB05130
    Experimental

    INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.

  8. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

  9. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  10. Drug

    Caprospinol

    go.drugbank.com/drugs/DB05263
    Experimental

    Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.